Related Experiment Videos
rhG-CSF in severe chronic neutropenia: successful intermittent treatment in three infants
D De Mattia1, G C Del Vecchio, P Ferrante
1Dipartimento di biomedicina dell'età Evolutiva, Università degli Studi di Bari, Italy.
Insights
Intermittent recombinant human granulocyte colony-stimulating factor (rhG-CSF) therapy effectively treats severe chronic neutropenia (SCN) in infants. This approach reduces infections and costs while maintaining treatment effectiveness and safety.
Area of Science:
- Pediatrics
- Hematology
- Immunology
Background:
- Severe chronic neutropenia (SCN) is a rare condition characterized by extremely low neutrophil counts.
- Recurrent infections and fevers are common complications in infants with SCN.
- Standard treatment involves daily recombinant human granulocyte colony-stimulating factor (rhG-CSF) to boost neutrophil production.
Observation:
- Three infants diagnosed with SCN were treated with rhG-CSF.
- The study explored an intermittent dosing regimen to improve patient compliance and reduce long-term therapy costs.
- The intermittent regimen involved subcutaneous injections of 3-10 micrograms/kg/d every 3-7 days.
Findings:
- Intermittent rhG-CSF therapy successfully maintained an absolute neutrophil count (ANC) between 0.5-1.5 x 10(9)/L.
- Patients experienced a significant reduction in the frequency and severity of infections.
- No significant adverse side effects were observed during the intermittent treatment period.
Implications:
- Intermittent rhG-CSF offers a potentially more cost-effective and manageable treatment option for pediatric SCN.
- This strategy may improve long-term adherence to therapy in children with chronic neutropenia.
- Further research can validate these findings in larger cohorts to establish intermittent rhG-CSF as a standard of care.
Abstract:
We report three cases of infants affected by severe chronic neutropenia (SCN). All the patients were treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF) to avoid or reduce recurrent fevers and severe infections. In order to obtain better compliance and reduce the costs of long-term therapy while achieving the same effectiveness of therapy, we decided to evaluate intermittent treatment in patients with SCN. With a single dose of 3-10 micrograms/kg/d subcutaneously every 3-7 days, the patient attained an absolute neutrophil count (ANC) of 0.5-1.5 x 10(9)/L, a reduction of infections, and no notable side effects.